Berenberg downgraded Sandoz to Hold from Buy with an unchanged price target of CHF 38. The firm struggles to find upside to earnings estimates after the Sandoz strategic update on September 3, saying no material updates to the pipeline were announced.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz price target raised to CHF 33 from CHF 28 at Deutsche Bank
- Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
- Sandoz Canada announces launch of Jubbonti, Wyost
- Sandoz receives FDA approval for Enzeevu
- Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
Questions or Comments about the article? Write to editor@tipranks.com